Electroencephalography (EEG) Biomarkers of Response in Depression

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

December 31, 2005

Conditions
Major Depressive Disorder
Interventions
DRUG

venlafaxine (Effexor)

Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.

DRUG

placebo

Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.

Trial Locations (1)

90024

UCLA Laboratory of Brain, Behavior, and Pharmacology, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic - MITG

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

University of California, Los Angeles

OTHER